These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9145977)

  • 41. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection.
    Gao X; Mohideen N; Flanigan RC; Waters WB; Wojcik EM; Leman CR
    J Urol; 2000 Dec; 164(6):1982-6. PubMed ID: 11061896
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Neoadjuvant therapy of prostate carcinoma].
    Ebert T
    Praxis (Bern 1994); 1997 Nov; 86(46):1815-8. PubMed ID: 9454282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression.
    Shimada K; Matsuyoshi S; Nakamura M; Ishida E; Konishi N
    J Pathol; 2005 Aug; 206(4):423-32. PubMed ID: 15906275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
    Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
    BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Immunohistochemical study of androgen receptor in adenocarcinoma of the human prostatic cancer].
    Yoshikawa H; Ikeuchi T; Kai Y
    Nihon Hinyokika Gakkai Zasshi; 1996 Jul; 87(7):956-63. PubMed ID: 8776961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Recent data about prostatic carcinoma (author's transl)].
    Coune A
    Rev Med Brux; 1980 May; 1(5):311-4. PubMed ID: 7466030
    [No Abstract]   [Full Text] [Related]  

  • 48. Apoptosis in prostatic adenocarcinoma following complete androgen ablation.
    Montironi R; Pomante R; Diamanti L; Magi-Galluzzi C
    Urol Int; 1998; 60 Suppl 1():25-9; discussion 30. PubMed ID: 9563141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complete histologic serial sectioning of a prostate gland with adenocarcinoma.
    Humphrey PA
    Am J Surg Pathol; 1993 May; 17(5):468-72. PubMed ID: 8470761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radical prostatectomy in locally advanced cancer - an indispensable onset of multimodal therapy?
    Malewski W; Dobruch J
    Cent European J Urol; 2017; 70(1):20-21. PubMed ID: 28466879
    [No Abstract]   [Full Text] [Related]  

  • 51. The role of chemotherapy and new targeted agents in the management of primary prostate cancer.
    Kumar SS; Pacey S
    J Clin Urol; 2016 Dec; 9(2 Suppl):30-37. PubMed ID: 28344814
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.
    Kim SH; Park WS; Kim SH; Park B; Joo J; Lee GK; Joung JY; Seo HK; Chung J; Lee KH
    PLoS One; 2016; 11(3):e0151646. PubMed ID: 26982980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
    Yee DS; Lowrance WT; Eastham JA; Maschino AC; Cronin AM; Rabbani F
    BJU Int; 2010 Jan; 105(2):185-90. PubMed ID: 19594741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.
    Mazzucchelli R; Barbisan F; Tagliabracci A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R
    Virchows Arch; 2007 Apr; 450(4):371-8. PubMed ID: 17285325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Therapy induced regressive changes of prostate cancer].
    Helpap B; Köllermann J
    Pathologe; 2004 Nov; 25(6):461-8. PubMed ID: 15221282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate cancer, Incidence, management and outcomes.
    Small EJ
    Drugs Aging; 1998 Jul; 13(1):71-81. PubMed ID: 9679210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathological changes in prostate lesions after androgen manipulation.
    Montironi R; Schulman CC
    J Clin Pathol; 1998 Jan; 51(1):5-12. PubMed ID: 9577363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma.
    Bazinet M; Zheng W; Bégin LR; Aprikian AG; Karakiewicz PI; Elhilali MM
    Urology; 1997 May; 49(5):721-5. PubMed ID: 9145977
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.